{
  "ticker": "SNDX",
  "company_name": "Syndax Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03978624",
      "title": "Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Bladder Cancer",
      "start_date": "2020-09-23",
      "completion_date": "2026-11-22",
      "enrollment": 0,
      "sponsor": "UNC Lineberger Comprehensive Cancer Center"
    },
    {
      "nct_id": "NCT05360160",
      "title": "A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Acute Myeloid Leukemia",
      "start_date": "2022-10-14",
      "completion_date": "2026-12-01",
      "enrollment": 0,
      "sponsor": "M.D. Anderson Cancer Center"
    },
    {
      "nct_id": "NCT02708680",
      "title": "Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Breast Cancer",
      "start_date": "2016-05",
      "completion_date": "2021-03-31",
      "enrollment": 0,
      "sponsor": "Syndax Pharmaceuticals"
    },
    {
      "nct_id": "NCT06226571",
      "title": "A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemias",
      "start_date": "2024-05-21",
      "completion_date": "2027-02",
      "enrollment": 0,
      "sponsor": "Syndax Pharmaceuticals"
    },
    {
      "nct_id": "NCT02437136",
      "title": "Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer",
      "start_date": "2015-08-26",
      "completion_date": "2022-09-29",
      "enrollment": 0,
      "sponsor": "Syndax Pharmaceuticals"
    },
    {
      "nct_id": "NCT02820961",
      "title": "Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Breast Cancer, Estrogen Receptor Positive Breast Cancer",
      "start_date": "2016-06-29",
      "completion_date": "2021-07-12",
      "enrollment": 0,
      "sponsor": "Syndax Pharmaceuticals"
    },
    {
      "nct_id": "NCT04065399",
      "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage",
      "start_date": "2019-11-05",
      "completion_date": "2027-12-15",
      "enrollment": 0,
      "sponsor": "Syndax Pharmaceuticals"
    },
    {
      "nct_id": "NCT04301778",
      "title": "Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Unresectable Intrahepatic Cholangiocarcinoma",
      "start_date": "2021-08-24",
      "completion_date": "2024-02-06",
      "enrollment": 0,
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
    },
    {
      "nct_id": "NCT01928576",
      "title": "Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Non-Small Cell Lung Cancer, Epigenetic Therapy",
      "start_date": "2013-11-06",
      "completion_date": "2023-04-04",
      "enrollment": 0,
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
    },
    {
      "nct_id": "NCT03361800",
      "title": "Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC",
      "status": "TERMINATED",
      "phase": "EARLY_PHASE1",
      "condition": "Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer",
      "start_date": "2018-11-28",
      "completion_date": "2019-10-11",
      "enrollment": 0,
      "sponsor": "UNC Lineberger Comprehensive Cancer Center"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 18,
      "PHASE1, PHASE2": 10,
      "PHASE1": 19,
      "EARLY_PHASE1": 1,
      "PHASE3": 1,
      "": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 4,
      "RECRUITING": 8,
      "COMPLETED": 25,
      "TERMINATED": 9,
      "NOT_YET_RECRUITING": 1,
      "NO_LONGER_AVAILABLE": 1,
      "WITHDRAWN": 2
    },
    "active_trials": 12,
    "completed_trials": 25,
    "conditions": [
      "Acute Leukemia",
      "Acute Myeloid Leukemia",
      "Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia",
      "Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage",
      "Acute Myeloid Leukemias",
      "Bladder Cancer",
      "Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged",
      "Breast Cancer",
      "Breast Cancer, Estrogen Receptor Positive Breast Cancer",
      "Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer",
      "Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer",
      "Chronic Graft-versus-host-disease",
      "Colorectal Cancer, Solid Tumors",
      "Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome",
      "Drug Interaction, Healthy Volunteer",
      "ER+ Breast Cancer",
      "Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer",
      "Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer",
      "Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma",
      "Hodgkin's Lymphoma",
      "Leukemia, HOX Gene",
      "Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer",
      "Lymphoma, Relapsed, Refractory",
      "Melanoma",
      "Metastatic Breast Cancer, Breast Cancer",
      "Metastatic Cancer, Renal Cancer",
      "Metastatic Cholangiocarcinoma, Cholangiocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Unresectable Cholangiocarcinoma",
      "Metastatic Uveal Melanoma",
      "Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Diseases, Renal Neoplasm, Solid Tumors",
      "Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Neoplasms, Breast Diseases, Renal Neoplasm, Solid Tumors",
      "Non Small Cell Lung Cancer",
      "Non-Small Cell Lung Cancer, Epigenetic Therapy",
      "Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer",
      "Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung",
      "Pancreas Cancer",
      "Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage",
      "Relapsed/Refractory Acute Leukemia",
      "Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia",
      "Renal Cell Carcinoma",
      "Renal Impairment, Healthy Volunteer",
      "Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm",
      "Unresectable Intrahepatic Cholangiocarcinoma",
      "Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:58.739184",
    "search_query": "Syndax Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Syndax+Pharmaceuticals,+Inc."
  }
}